Skip to main content

Infection

18
Pipeline Programs
27
Companies
41
Clinical Trials
3 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
1
0
8
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
4100%
+ 42 programs with unclassified modality

On Market (2)

Approved therapies currently available

Pfizer
ACHES-N-PAINApproved
ibuprofen
Pfizer
oral1987
Baxter
BUPIVACAINE HYDROCHLORIDEApproved
bupivacaine hydrochloride
Baxter
spinal2016

Competitive Landscape

26 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
9 programs
2
1
1
MagnexPhase 41 trial
IbuprofenPhase 3Small Molecule1 trial
metronidazole IV 500 mgPhase 11 trial
moxidectinPhase 12 trials
A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, EcoliN/A1 trial
+4 more programs
Active Trials
NCT00724919Completed256Est. Apr 2004
NCT00366223Completed80Est. Jun 2017
NCT00900952Completed240Est. Jun 2009
+7 more trials
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
5 programs
3
1
MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 DaysPhase 4
MK0826, ertapenem sodium / Duration of Treatment: 14 DaysPhase 3
Truvada and IsentressPhase 3
ertapenem sodiumPhase 3
APPI of TKR-StimulanN/A1 trial
Active Trials
NCT02107924Withdrawn0Est. Dec 2015
MSD
MSDIreland - Ballydine
4 programs
3
1
MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 DaysPhase 41 trial
MK0826, ertapenem sodium / Duration of Treatment: 14 DaysPhase 31 trial
Truvada and IsentressPhase 31 trial
ertapenem sodiumPhase 31 trial
Active Trials
NCT00398099Completed30Est. Jan 2006
NCT01697046Unknown65Est. Mar 2014
NCT01254344Completed599Est. Dec 2011
+1 more trials
Baxter
BaxterCosta Rica - Cartago
1 program
1
BUPIVACAINE HYDROCHLORIDE(Peripheral Intravenous Analysis)N/A
Bayer
BayerLEVERKUSEN, Germany
4 programs
1
1
MoxifloxacinPhase 3Small Molecule1 trial
Cipro InhalePhase 11 trial
CiproN/A1 trial
CiprofloxacinN/ASmall Molecule1 trial
Active Trials
NCT01690559Completed704Est. Jan 2012
NCT01670435Completed3,274Est. Oct 2010
NCT01168895Completed12Est. Sep 2010
+1 more trials
Theravance Biopharma
1 program
1
TelavancinPhase 21 trial
Active Trials
NCT01321879Completed40Est. Dec 2016
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
rifampinPhase 11 trial
Early Diagnosis of Candidiasis in Premature InfantsN/A1 trial
Active Trials
NCT00109525Completed1,500Est. Dec 2009
NCT01441206Terminated2Est. Apr 2012
Sandoz
SandozAustria - Kundl
2 programs
Azithromycin Monohydrate 600 mg TabletsPHASE_11 trial
Azithromycin Monohydrate 600mg Tablets Geneva PharmaceuticalsPHASE_11 trial
Active Trials
NCT00865670Completed38Est. Sep 2003
NCT00866216Completed38Est. Sep 2003
Innovation Pharmaceuticals
1 program
A new model of interaction across health services with use of welfare technology and telemedicineN/A1 trial
Active Trials
NCT04898452Recruiting50Est. Dec 2026
Vygon
VygonFrance - Ecouen
1 program
BionecteurN/A1 trial
Active Trials
NCT02134769Completed221Est. Dec 2015
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Characterize alcohol and drug useN/A1 trial
Active Trials
NCT02299921Recruiting300Est. Apr 2029
Forte Biosciences
1 program
CultureN/A1 trial
Active Trials
NCT02602548Completed100Est. Mar 2018
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Diagnosis and Management of Inflammatory and Infectious DiseasesN/A1 trial
Active Trials
NCT00557726Recruiting400
Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
1 program
Home hospitalizationN/A1 trial
Active Trials
NCT03203759Completed91Est. May 2018
Plus Therapeutics
1 program
Novel Microbicidal Liquid PolymerN/A1 trial
Active Trials
NCT03756506CompletedEst. Sep 2019
Baxter International
1 program
Peripheral Intravenous AnalysisN/A1 trial
Active Trials
NCT03736421Terminated50Est. Oct 2021
Stryker
StrykerCA - San Jose
1 program
Post Market Clinical Follow Up Study for Evaluation of Agluna® METSN/A1 trial
Active Trials
NCT02779504Completed51Est. Dec 2016
Abbott
AbbottABBOTT PARK, IL
1 program
Procurement of Human Specimens for the Evaluation of Early Markers of SepsisN/A1 trial
Active Trials
NCT01746407Completed872Est. Dec 2014
Thermo Fisher Scientific
1 program
Technical Evaluation of Brahms PCT DirectN/A1 trial
Active Trials
NCT01771029Completed150Est. Sep 2014
Parexel
ParexelMA - Boston
1 program
Cefazolin 2g for Injection USP and Dextrose Injection USPPHASE_1
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
caspofungin acetatePHASE_21 trial
Active Trials
NCT00238355Terminated13Est. Jun 2008
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
Hantavax injectionPHASE_31 trial
Active Trials
NCT02360514Completed226Est. Oct 2012
Vertex Pharmaceuticals
1 program
Pegylated Interferon Alfa 2aPHASE_31 trial
Active Trials
NCT01821963Terminated1Est. Feb 2014
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 DaysPHASE_4
Sanofi
SanofiPARIS, France
1 program
TeicoplaninPHASE_42 trials
Active Trials
NCT04003818Terminated50Est. Mar 2021
NCT00454272Completed197Est. Aug 2007
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
leukocyte depletion of whole bloodPHASE_41 trial
Active Trials
NCT00176124Completed1,089Est. Sep 2005

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
SanofiTeicoplanin
MSDMK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days
SanofiTeicoplanin
PfizerMagnex
Heidelberg Pharmaleukocyte depletion of whole blood
Vertex PharmaceuticalsPegylated Interferon Alfa 2a
MSDTruvada and Isentress
MSDertapenem sodium
PfizerIbuprofen
GC BiopharmaHantavax injection
BayerMoxifloxacin
MSDMK0826, ertapenem sodium / Duration of Treatment: 14 Days
Theravance BiopharmaTelavancin
Knight Therapeuticscaspofungin acetate
Human BioSciencesrifampin

Showing 15 of 41 trials with date data

Clinical Trials (41)

Total enrollment: 13,658 patients across 41 trials

Efficacy and Safety of Teicoplanin in CDAD

Start: May 2020Est. completion: Mar 202150 patients
Phase 4Terminated
NCT00445094MSDMK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

Start: Nov 2006Est. completion: Jan 2007120 patients
Phase 4Completed

Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients

Start: Jan 2005Est. completion: Aug 2007197 patients
Phase 4Completed

A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections

Start: Jul 2004Est. completion: Apr 2005307 patients
Phase 4Completed
NCT00176124Heidelberg Pharmaleukocyte depletion of whole blood

Leukocyte Depletion of Autologous Whole Blood

Start: Apr 2001Est. completion: Sep 20051,089 patients
Phase 4Completed
NCT01821963Vertex PharmaceuticalsPegylated Interferon Alfa 2a

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Start: Apr 2013Est. completion: Feb 20141 patients
Phase 3Terminated
NCT01697046MSDTruvada and Isentress

A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection

Start: Nov 2012Est. completion: Mar 201465 patients
Phase 3Unknown
NCT01254344MSDertapenem sodium

Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)

Start: Dec 2010Est. completion: Dec 2011599 patients
Phase 3Completed

Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection

Start: Jan 2010Est. completion: May 201116 patients
Phase 3Terminated
NCT02360514GC BiopharmaHantavax injection

Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS

Start: Dec 2007Est. completion: Oct 2012226 patients
Phase 3Completed
NCT00492726BayerMoxifloxacin

Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

Start: Jul 2006Est. completion: Feb 2009804 patients
Phase 3Completed
NCT00398099MSDMK0826, ertapenem sodium / Duration of Treatment: 14 Days

To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)

Start: Jul 2005Est. completion: Jan 200630 patients
Phase 3Completed

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Start: Mar 2011Est. completion: Dec 201640 patients
Phase 2Completed

Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

Start: Aug 2003Est. completion: Jun 200813 patients
Phase 2Terminated

Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants

Start: Sep 2011Est. completion: Apr 20122 patients
Phase 1Terminated
NCT01407016Pfizermetronidazole IV 500 mg

A Study To Assess The Safety, Tolerability And Pharmacokinetics Of Metronidazole Injection In Healthy Japanese Subjects

Start: Aug 2011Est. completion: Sep 20116 patients
Phase 1Completed
NCT01168895BayerCipro Inhale

Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder

Start: Jul 2010Est. completion: Sep 201012 patients
Phase 1Completed

Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin

Start: Nov 2008Est. completion: May 200954 patients
Phase 1Completed

Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women

Start: Nov 2008Est. completion: Sep 200912 patients
Phase 1Completed
NCT00865670SandozAzithromycin Monohydrate 600 mg Tablets

To Demonstrate the Relative Bioavailability of Azithromycin 600 mg Tablets Under Fed Conditions

Start: Aug 2003Est. completion: Sep 200338 patients
Phase 1Completed
NCT00866216SandozAzithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals

Comparative Bioavailability Study of 600mg Azithromycin Monohydrate Tablets Under Fasting Conditions

Start: Aug 2003Est. completion: Sep 200338 patients
Phase 1Completed
NCT04898452Innovation PharmaceuticalsA new model of interaction across health services with use of welfare technology and telemedicine

Intravenous Antibiotic Treatment at Home

Start: Jul 2020Est. completion: Dec 202650 patients
N/ARecruiting
NCT03923426PfizerZavicefta Treatment

Real-World Observational Study Of Zavicefta to Characterize Use Patterns

Start: Nov 2018Est. completion: Mar 2022572 patients
N/ACompleted
NCT03736421Baxter InternationalPeripheral Intravenous Analysis

Observational Study to Evaluate Peripheral IntraVenous Analysis (PIVA) in Euvolemic, Hypovolemic, and Hypervolemic Emergency Department Patients

Start: Nov 2018Est. completion: Oct 202150 patients
N/ATerminated
NCT03756506Plus TherapeuticsNovel Microbicidal Liquid Polymer

The Use of a Novel Microbicidal Liquid Polymer for the Reduction of Pin Track Infection

Start: Nov 2018Est. completion: Sep 2019
N/ACompleted
NCT03203759Connect BiopharmaHome hospitalization

Hospital-Level Care at Home for Acutely Ill Adults

Start: Jun 2017Est. completion: May 201891 patients
N/ACompleted
NCT02779504StrykerPost Market Clinical Follow Up Study for Evaluation of Agluna® METS

Post Market Clinical Follow Up Study for Evaluation of Agluna® METS

Start: May 2016Est. completion: Dec 201651 patients
N/ACompleted

The Incidence and Incubation Period of False Positive Cultures in Shoulder Surgery

Start: May 2015Est. completion: Mar 2018100 patients
N/ACompleted
NCT02299921Colorado TherapeuticsCharacterize alcohol and drug use

Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure

Start: Nov 2014Est. completion: Apr 2029300 patients
N/ARecruiting

Influence of Bionecteurs on Catheter-associated Infection

Start: Aug 2014Est. completion: Dec 2015221 patients
N/ACompleted
NCT02107924Sharp TherapeuticsAPPI of TKR-Stimulan

Use of Antibiotic Carrier in Acute Periprosthetic Infections (APPI) of Total Knee Replacements

Start: Apr 2014Est. completion: Dec 20150
N/AWithdrawn
NCT01771029Thermo Fisher ScientificTechnical Evaluation of Brahms PCT Direct

Technical Evaluation of Brahms PCT Direct

Start: Feb 2013Est. completion: Sep 2014150 patients
N/ACompleted
NCT01746407AbbottProcurement of Human Specimens for the Evaluation of Early Markers of Sepsis

Procurement of Human Specimens for the Evaluation of Early Markers of Sepsis

Start: Dec 2012Est. completion: Dec 2014872 patients
N/ACompleted

Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution

Start: Apr 2010Est. completion: Jan 2012704 patients
N/ACompleted
NCT00900952PfizerClinical record review

Epidemiologic Study Evaluating Infections in Elderly Patients

Start: Mar 2009Est. completion: Jun 2009240 patients
N/ACompleted
NCT01670435BayerCiprofloxacin

Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance

Start: May 2007Est. completion: Oct 20103,274 patients
N/ACompleted

A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting

Start: Nov 2006Est. completion: Mar 20101,028 patients
N/ACompleted
NCT00366223PfizerChanging Patterns of Candida Infections in Urban Medical Centers

Changing Patterns of Candida Infections in Urban Medical Centers

Start: Aug 2006Est. completion: Jun 201780 patients
N/ACompleted
NCT00109525Human BioSciencesEarly Diagnosis of Candidiasis in Premature Infants

Early Diagnosis of Candidiasis in Premature Infants

Start: Mar 2004Est. completion: Dec 20091,500 patients
N/ACompleted
NCT00724919PfizerA Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

Start: Dec 2003Est. completion: Apr 2004256 patients
N/ACompleted
NCT00557726Allergy TherapeuticsDiagnosis and Management of Inflammatory and Infectious Diseases

Diagnosis and Management of Inflammatory and Infectious Diseases

Start: Feb 1978400 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

8 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 13,658 patients
27 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.